These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 28649891)

  • 1. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
    Pierro J; Hogan LE; Bhatla T; Carroll WL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapy for childhood acute lymphoblastic leukemia.
    Santiago R; Vairy S; Sinnett D; Krajinovic M; Bittencourt H
    Expert Opin Pharmacother; 2017 Aug; 18(11):1081-1099. PubMed ID: 28608730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
    Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
    Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agents in Development for Childhood Acute Lymphoblastic Leukemia.
    Maloney KW; Gore L
    Paediatr Drugs; 2018 Apr; 20(2):111-120. PubMed ID: 29143289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
    Ronson A; Tvito A; Rowe JM
    Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
    Algeri M; Del Bufalo F; Galaverna F; Locatelli F
    Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapsed childhood acute lymphoblastic leukaemia.
    Bhojwani D; Pui CH
    Lancet Oncol; 2013 May; 14(6):e205-17. PubMed ID: 23639321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
    Jabbour E; Pui CH; Kantarjian H
    JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the treatment of acute lymphoblastic leukemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging biological therapies to treat acute lymphoblastic leukemia.
    Huguet F; Tavitian S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches.
    Locatelli F; Moretta F; Rutella S
    Curr Opin Oncol; 2013 Nov; 25(6):707-15. PubMed ID: 24076579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.
    Irving JA
    Br J Haematol; 2016 Mar; 172(5):655-66. PubMed ID: 26568036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
    Maino E; Bonifacio M; Scattolin AM; Bassan R
    Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
    Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
    Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
    Wyatt KD; Bram RJ
    Hum Immunol; 2019 Jun; 80(6):400-408. PubMed ID: 30716352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch signaling as a therapeutic target for acute lymphoblastic leukemia.
    Bellavia D; Palermo R; Felli MP; Screpanti I; Checquolo S
    Expert Opin Ther Targets; 2018 Apr; 22(4):331-342. PubMed ID: 29527929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of cellular immunotherapy for childhood leukemia.
    Bonifant CL; Tasian SK
    Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular-based and antibody-based targeted pharmacological approaches in childhood acute lymphoblastic leukemia.
    Tardif M; Souza A; Krajinovic M; Bittencourt H; Tran TH
    Expert Opin Pharmacother; 2021 Oct; 22(14):1871-1887. PubMed ID: 34011251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.